BACKGROUND: The effect of β-blockade in trauma patients without significant head injuries is unknown. The purpose of this investigation was to determine the impact of β-blocker exposure on mortality in critically injured trauma patients who did not sustain significant head injuries. METHODS: Critically ill trauma patients (Injury Severity Score ≥ 25) admitted to the surgical intensive care unit from January 2000 to December 2008 without severe traumatic brain injuries (head Abbreviated Injury Score ≥ 3) were included in this retrospective review. Patients who received β-blockers within 30 days of intensive care unit admission were compared with those who did not. The primary outcome measure evaluated was in-hospital mortality. RESULTS: During the 9-year study period, 663 critically injured patients (Injury Severity Score ≥ 25) were admitted to the intensive care unit. Of these, 98 patients (14.8%) received β-blockers. Patients exposed to β-blockers had significantly lower in-hospital mortality (11.2% vs 19.3%, P = .006). Stepwise logistic regression identified β-blocker use as an independent protective factor for mortality (adjusted odds ratio, .37; P = .007) in critically injured patients. CONCLUSIONS: Beta-blocker exposure was associated with reduced mortality in critically injured patients without head injuries. Prospective validation of this finding is warranted.
BACKGROUND: The effect of β-blockade in traumapatients without significant head injuries is unknown. The purpose of this investigation was to determine the impact of β-blocker exposure on mortality in critically injured traumapatients who did not sustain significant head injuries. METHODS:Critically ill traumapatients (Injury Severity Score ≥ 25) admitted to the surgical intensive care unit from January 2000 to December 2008 without severe traumatic brain injuries (head Abbreviated Injury Score ≥ 3) were included in this retrospective review. Patients who received β-blockers within 30 days of intensive care unit admission were compared with those who did not. The primary outcome measure evaluated was in-hospital mortality. RESULTS: During the 9-year study period, 663 critically injured patients (Injury Severity Score ≥ 25) were admitted to the intensive care unit. Of these, 98 patients (14.8%) received β-blockers. Patients exposed to β-blockers had significantly lower in-hospital mortality (11.2% vs 19.3%, P = .006). Stepwise logistic regression identified β-blocker use as an independent protective factor for mortality (adjusted odds ratio, .37; P = .007) in critically injured patients. CONCLUSIONS: Beta-blocker exposure was associated with reduced mortality in critically injured patients without head injuries. Prospective validation of this finding is warranted.
Authors: Aziz S Alali; Kaushik Mukherjee; Victoria A McCredie; Eyal Golan; Prakesh S Shah; James M Bardes; Susan E Hamblin; Elliott R Haut; James C Jackson; Kosar Khwaja; Nimitt J Patel; Satish R Raj; Laura D Wilson; Avery B Nathens; Mayur B Patel Journal: Ann Surg Date: 2017-12 Impact factor: 12.969
Authors: Ahmad Mohammad Ismail; Tomas Borg; Gabriel Sjolin; Arvid Pourlotfi; Sebastian Holm; Yang Cao; Per Wretenberg; Rebecka Ahl; Shahin Mohseni Journal: Trauma Surg Acute Care Open Date: 2020-07-29
Authors: Tyler J Loftus; Martin D Rosenthal; Chasen A Croft; R Stephen Smith; Frederick A Moore; Scott C Brakenridge; Philip A Efron; Alicia M Mohr Journal: J Surg Res Date: 2018-06-28 Impact factor: 2.192
Authors: Pär I Johansson; John Bro-Jeppesen; Jesper Kjaergaard; Michael Wanscher; Christian Hassager; Sisse R Ostrowski Journal: PLoS One Date: 2015-03-19 Impact factor: 3.240
Authors: Pär I Johansson; Hanne H Henriksen; Jakob Stensballe; Mikkel Gybel-Brask; Jessica C Cardenas; Lisa A Baer; Bryan A Cotton; John B Holcomb; Charles E Wade; Sisse R Ostrowski Journal: Ann Surg Date: 2017-03 Impact factor: 12.969